NCT06122389View on ClinicalTrials.gov

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

July 31, 2026

Conditions
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Interventions
DRUG

SHR2554; Chidamide analog tablets

SHR2554 + Chidamide analog tablets

DRUG

SHR2554 analog tablets; Chidamide

SHR2554 analog tablets + Chidamide

Trial Locations (1)

100000

RECRUITING

Peking University Cancer Hospital, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY